Related Experiment Video
Updated: Jul 30, 2026
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
Fetal circular shunt in Ebstein's anomaly and non-steroidal anti-inflammatory treatment
F L Peña1, T W Emanuelson1, S H Todman1
1Louisiana State University Health Shreveport, Shreveport, LA, USA.
Insights
Prenatal non-steroidal anti-inflammatory drugs (NSAIDs) can effectively constrict the ductus arteriosus (DA), improving outcomes for fetuses with Ebstein's anomaly and circular shunts. This treatment significantly reduces fetal demise and hydrops.
Area of Science:
- Cardiology
- Fetal Medicine
- Pharmacology
Background:
- Circular shunts are a significant negative prognostic indicator in Ebstein's anomaly.
- Constriction of the ductus arteriosus (DA) is a therapeutic target to mitigate circular shunts and improve fetal prognosis.
- Prenatal non-steroidal anti-inflammatory drugs (NSAIDs) are known to induce DA constriction.
Purpose of the Study:
- To review the literature on the effectiveness and outcomes of using prenatal NSAIDs to treat circular shunts in fetuses.
- To evaluate the impact of NSAID-induced ductal constriction on fetal survival and hydrops resolution.
Main Methods:
- Extensive literature review.
- Analysis of studies reporting the use of prenatal NSAIDs for ductal constriction in fetal Ebstein's anomaly.
- Evaluation of fetal outcomes including ductal patency, fetal demise, and hydrops resolution.
Main Results:
- Prenatal NSAID therapy achieved ductal constriction in 82% of fetuses.
- Fetal demise was significantly lower (6%) in fetuses with NSAID-induced ductal constriction compared to those without (50%).
- Hydrops resolved in 50% of fetuses treated with prenatal NSAIDs.
Conclusions:
- Prenatal NSAID therapy is an effective strategy for inducing ductal constriction in fetuses with Ebstein's anomaly and circular shunts.
- Successful ductal constriction via NSAIDs is associated with improved fetal survival and a higher likelihood of hydrops resolution.
- This therapeutic approach offers a promising intervention for managing complex fetal cardiac conditions.
Abstract:
A circular shunt is a poor prognostic factor associated with Ebstein's anomaly. Targeting the constriction of the ductus arteriosus (DA) in order to limit or resolve the circular shunt, has been shown to improve fetal outcomes. Prenatal non-steroidal anti-inflammatory drugs (NSAIDs) have been known to constrict the DA. Recently, prenatal NSAIDs have been used for that purpose in the treatment of circular shunt. Limited research shows that it may be an effective treatment leading to improved fetal outcomes. In this article, we did an extensive review of literature to describe this therapy's effectiveness and outcomes. 82% of fetuses were able to achieve ductal constriction with prenatal NSAID therapy. For fetuses who achieved ductal constriction, fetal demise was less likely (6%) when compared to those who were unable to achieve the same (50%). Of all the fetuses with hydrops, 50% had resoluation of hydrops with prenatal NSAID treatment.
